Literature DB >> 30167781

[(Immuno‑)Pathology of drug side effects in the kidney].

F Pfister1, M Büttner-Herold1, K Amann2.   

Abstract

Nephrotoxicity or renal side effects of drugs are frequent and may vary in their clinical presentation. Various types of acute and chronic kidney disease are known to develop as a consequence or side effect of a long list of drugs with nephrotoxicity most commonly being associated with injury in the tubulointerstitial compartment. In addition, drug-induced glomerular and vascular disease have also been reported, either as the result of direct cellular injury or immune-mediated injury to glomerular or endothelial cells. From a clinical point of view it is important to recognize such drug-induced nephropathies early in order to prevent or adequately treat them to favour kidney recovery and to avoid long-lasting negative consequences for kidney function.This article will focus on the typical morphology and pathogenesis of some frequent drug-induced renal diseases.

Entities:  

Keywords:  Drug-related side effects and adverse reactions; Immunopathology; Interstitial nephritis; Thrombotic microangiopathies; Tubular damage, acute

Mesh:

Year:  2018        PMID: 30167781     DOI: 10.1007/s00292-018-0475-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

Review 1.  Drug-induced glomerular disease: attention required!

Authors:  Jai Radhakrishnan; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

2.  Hydralazine associated pauci-immune glomerulonephritis.

Authors:  Manish Suneja; Shalanki Baiswar; Scott A Vogelgesang
Journal:  J Clin Rheumatol       Date:  2014-03       Impact factor: 3.517

3.  Both PD-1 ligands protect the kidney from ischemia reperfusion injury.

Authors:  Katarzyna Jaworska; Joanna Ratajczak; Liping Huang; Kristen Whalen; Mana Yang; Brian K Stevens; Gilbert R Kinsey
Journal:  J Immunol       Date:  2014-11-17       Impact factor: 5.422

4.  Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses.

Authors:  Astrid Starke; Maja T Lindenmeyer; Stephan Segerer; Matthias A Neusser; Barbara Rüsi; Daniel M Schmid; Clemens D Cohen; Rudolf P Wüthrich; Thomas Fehr; Ying Waeckerle-Men
Journal:  Kidney Int       Date:  2010-04-14       Impact factor: 10.612

Review 5.  Accessible miRNAs as Novel Toxicity Biomarkers.

Authors:  Wendy J Bailey; Warren E Glaab
Journal:  Int J Toxicol       Date:  2018-01-22       Impact factor: 2.032

6.  PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.

Authors:  Ying Waeckerle-Men; Astrid Starke; Rudolf P Wüthrich
Journal:  Nephrol Dial Transplant       Date:  2007-03-05       Impact factor: 5.992

7.  Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.

Authors:  Sandhya Manohar; Panagiotis Kompotiatis; Charat Thongprayoon; Wisit Cheungpasitporn; Joerg Herrmann; Sandra M Herrmann
Journal:  Nephrol Dial Transplant       Date:  2019-01-01       Impact factor: 5.992

8.  Hydralazine-induced ANCA-positive pauci-immune glomerulonephritis: a case report and literature review.

Authors:  Mirela Dobre; Jay Wish; Lavinia Negrea
Journal:  Ren Fail       Date:  2009       Impact factor: 2.606

9.  Phenotype standardization for drug-induced kidney disease.

Authors:  Ravindra L Mehta; Linda Awdishu; Andrew Davenport; Patrick T Murray; Etienne Macedo; Jorge Cerda; Raj Chakaravarthi; Arthur L Holden; Stuart L Goldstein
Journal:  Kidney Int       Date:  2015-04-08       Impact factor: 10.612

10.  IgA-Dominant Glomerulopathy and Thrombotic Microangiopathy After Chemotherapy.

Authors:  Zeljko Dvanajscak; Bethany E Karl; Amber P Sanchez; Vighnesh Walavalkar
Journal:  Kidney Int Rep       Date:  2017-11-03
View more
  2 in total

1.  Polygala fallax Hemsl combined with compound Sanqi granules relieves glomerulonephritis by regulating proliferation and apoptosis of glomerular mesangial cells.

Authors:  Shiwei Chao; Qin Xu; Shaoning Dong; Min Guo; Xusheng Liu; Xueren Cheng
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

2.  [Side effects of novel cancer immunotherapies].

Authors:  G S Braun; M Kirschner; A Rübben; R U Wahl; K Amann; K Benesova; J Leipe
Journal:  Nephrologe       Date:  2020-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.